NR4A1 and obesity disorder: Jastreboff Jastreboff AM AM Kaplan Kaplan LM LM Frías Frías JP JP Triple-hormone-receptor agonist retatrutide for obesity—A Phase 2 Trial Triple-hormone-receptor agonist retatrutide for obesity—A Phase 2 Trial N Engl J Med N Engl J Med 2023 2023 2023 2023 389 389 514 514 526 526 10.1056/NEJMoa2301972 10.1056/NEJMoa2301972 Jastreboff AM, Kaplan LM, Frías JP et al (2023) Triple-hormone-receptor agonist retatrutide for obesity—A Phase 2 Trial.